Fig. 1Distribution of Korean version of the hyperthyroidism symptom scale.
Fig. 2(A) Distribution of thyroid stimulating hormone (TSH) and (B) Korean version of the hyperthyroidism symptom scale (K-HSS) in subclinically thyrotoxic and euthyroid posttreatment patients and control group at follow-up.
Table 1Baseline Characteristics of Participants
Characteristic |
Control group (n=10) |
Patient group (n=28) |
P value |
Age, yr |
34.1±5.9 |
34.9±10.9 |
0.787 |
Male sex, % |
30.0 |
35.7 |
0.744 |
BMI, kg/m2
|
20.7±1.6 |
20.6±4.7 |
0.932 |
SBP, mm Hg |
124.6±11.4 |
130.2±14.3 |
0.274 |
DBP, mm Hg |
70.6±9.6 |
78.1±10.6 |
0.057 |
HR, bpm |
81.9±14.8 |
101.6±14.5 |
0.001 |
Free T4, ng/dL |
1.4±0.1 |
3.1±1.1 |
<0.001 |
TSH, µIU/mL |
1.3 (1.1–2.3) |
0.0 (0.0–0.0) |
<0.001 |
TSH receptor Ab, IU/L |
0.0 (0.0–0.0) |
9.5 (5.6–18.3) |
<0.001 |
K-HSS |
0.5 (0.0–2.8) |
12.5 (8.0–18.0) |
<0.001 |
Glucose, mg/dL |
96.6±23.1 |
105.8±18.6 |
0.243 |
Total protein, g/dL |
7.2±0.4 |
7.1±0.5 |
0.372 |
Albumin, g/dL |
4.4±0.3 |
4.3±0.3 |
0.179 |
Total bilirubin, mg/dL |
0.7±0.3 |
0.7±0.3 |
0.497 |
ALP, IU/L |
53.2±12.6 |
147.8±160.9 |
0.074 |
AST, IU/L |
18.3±3.1 |
26.4±10.4 |
0.001 |
ALT, IU/L |
15.1±7.9 |
33.1±22.0 |
0.017 |
WBC, ×103/µL |
5.8±1.4 |
5.5±1.7 |
0.610 |
Hemoglobin, g/dL |
13.6±1.4 |
14.0±1.4 |
0.424 |
Platelets, ×103/µL |
276.6±59.1 |
243.0±59.0 |
0.149 |
Table 2Comparison of Thyroid Function Test and K-HSS between Baseline and Posttreatment/Follow-up in Patient and Control Groups
|
Patient groupa (n=25) |
Control group (n=10) |
P valuec
|
Baseline |
Posttreatment |
P valueb
|
Baseline |
Follow-up |
P valueb
|
Free T4 |
3.0±1.1 |
1.5±0.5 |
<0.001 |
1.4±0.1 |
1.4±0.1 |
NA |
0.950 |
TSH |
0.0 (0.0–0.0) |
0.0 (0–0.4) |
0.051 |
1.3 (1.1–2.3) |
1.6 (1.0–3.2) |
0.445 |
<0.001 |
K-HSS |
12.0 (8.0–17.8) |
4.0 (2.0–7.0) |
<0.001 |
0.5 (0.0–2.8) |
0.0 (0.0–2.0) |
0.496 |
0.001 |
Table 3Comparison of Thyroid Function Test and K-HSS between Subclinical Thyrotoxic and Euthyroid Posttreatment Patients, Euthyroid Posttreatment Patients and Control Group at Follow-up
|
Posttreatment of patient groupa (n=25) |
Control group at follow-up (n=10) |
P valueb
|
Subclinical thyrotoxic (n=19) |
Euthyroid (n=6) |
Free T4 |
1.4±0.1 |
1.2±0.4 |
1.4±0.3 |
0.227 |
TSH |
0.0 (0.0–0.0) |
1.5 (0.5–3.9) |
1.6 (1.0–3.2) |
<0.001 |
K-HSS |
4.0 (2.5–7.5) |
3.0 (0.5–10.8) |
0.0 (0.0–2.0) |
0.004 |
Table 4Comparison of Scores at Baseline and Posttreatment/Follow-up for Each Item Included in the K-HSS
|
Baseline |
Posttreatment/Follow-up |
P value |
Patients group (n=25) |
|
|
|
Total |
12.0 (7.8–18.0) |
3.0 (1.0–7.5) |
<0.001 |
K-HSS, #1 (nervousness) |
1.0 (0.0–2.0) |
0.0 (0.0–1.0) |
0.002 |
K-HSS, #2 (diaphoresis) |
1.0 (0.0–2.0) |
0.0 (0.0–2.0) |
0.017 |
K-HSS, #3 (heat intolerance) |
1.0 (1.0–2.5) |
1.0 (0.0–1.0) |
0.001 |
K-HSS, #4 (motor activity) |
1.0 (0.0–2.0) |
0.0 (0.0–1.0) |
0.047 |
K-HSS, #5 (tremor) |
2.0 (0.0–2.0) |
0.0 (0.0–0.5) |
0.002 |
K-HSS, #6 (weakness) |
1.0 (1.0–2.5) |
0.0 (0.0–0.5) |
<0.001 |
K-HSS, #7 (hyperdynamic precordium) |
2.0 (1.0–3.0) |
0.0 (0.0–2.0) |
0.001 |
K-HSS, #8 (diarrhea) |
1.0 (0.0 –1.0) |
0.0 (0.0–0.0) |
0.003 |
K-HSS, #9 (weight loss/appetite) |
1.0 (0.0–2.5) |
0.0 (0.0–1.0) |
0.050 |
K-HSS, #10 (overall function) |
1.0 (0.0–2.0) |
0.0 (0.0–1.0) |
0.002 |
Control group (n=10) |
|
|
|
Total |
0.5 (0.0–2.8) |
0.0 (0.0–2.0) |
0.496 |
K-HSS, #1 (nervousness) |
0.0 (0.0–1.0) |
0.0 (0.0–1.0) |
1.000 |
K-HSS, #2 (diaphoresis) |
0.0 (0.0–0.3) |
0.0 (0.0–0.0) |
0.157 |
K-HSS, #3 (heat intolerance) |
0.0 (0.0–0.0) |
0.0 (0.0–0.0) |
1.000 |
K-HSS, #4 (motor activity) |
0.0 (0.0–0.3) |
0.0 (0.0–0.3) |
1.000 |
K-HSS, #5 (tremor) |
0.0 (0.0–0.0) |
0.0 (0.0–0.0) |
1.000 |
K-HSS, #6 (weakness) |
0.0 (0.0–0.0) |
0.0 (0.0–0.0) |
1.000 |
K-HSS, #7 (hyperdynamic precordium) |
0.0 (0.0–0.0) |
0.0 (0.0–0.0) |
1.000 |
K-HSS, #8 (diarrhea) |
0.0 (0.0–0.0) |
0.0 (0.0–0.0) |
0.317 |
K-HSS, #9 (weight loss/appetite) |
0.0 (0.0–0.3) |
0.0 (0.0–0.0) |
0.317 |
K-HSS, #10 (overall function) |
0.0 (0.0–0.0) |
0.0 (0.0–0.0) |
0.317 |